Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw.

Son HJ, Kim JW, Kim SJ.

Maxillofac Plast Reconstr Surg. 2019 Jul 23;41(1):26. doi: 10.1186/s40902-019-0210-8. eCollection 2019 Dec.

2.
3.

[Clinical analysis of 24 cases of bisphosphonate-related osteonecrosis of the jaw].

Guo Y, Wang D, An J, Peng X, Cai Z, Guo C.

Zhonghua Kou Qiang Yi Xue Za Zhi. 2014 Sep;49(9):517-20. Chinese.

PMID:
25476210
4.

Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.

Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.

Oncologist. 2008 Aug;13(8):911-20. doi: 10.1634/theoncologist.2008-0091. Epub 2008 Aug 11.

5.

[Bisphosphonate-associated osteonecrosis of the jaw].

Abu-Id MH, Açil Y, Gottschalk J, Kreusch T.

Mund Kiefer Gesichtschir. 2006 Mar;10(2):73-81. Review. German.

PMID:
16456688
6.

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.

Grant BT, Amenedo C, Freeman K, Kraut RA.

J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019.

PMID:
18201600
7.

Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.

Wasserzug O, Kaffe I, Lazarovici TS, Weissman T, Yahalom R, Fliss DM, Yarom N.

Am J Rhinol Allergy. 2017 Jan 1;31(1):36-39. doi: 10.2500/ajra.2017.31.4395. Review.

PMID:
28234151
8.

Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.

Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C.

J Craniomaxillofac Surg. 2012 Jun;40(4):303-9. doi: 10.1016/j.jcms.2011.05.003. Epub 2011 Jun 14.

PMID:
21676622
9.

Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature.

Cavanna L, Bertè R, Arcari A, Mordenti P, Pagani R, Vallisa D.

Eur J Intern Med. 2007 Sep;18(5):417-22. Epub 2007 Jul 13.

PMID:
17693231
10.

Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.

Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.

Oral Oncol. 2008 Sep;44(9):857-69. doi: 10.1016/j.oraloncology.2007.11.012. Epub 2008 Feb 20.

PMID:
18282788
11.

Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions.

Ripamonti CI, Maniezzo M, Boldini S, Pessi MA, Mariani L, Cislaghi E.

J Bone Oncol. 2012 Sep 24;1(3):81-7. doi: 10.1016/j.jbo.2012.08.001. eCollection 2012 Dec.

12.

A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.

Kwon JW, Park EJ, Jung SY, Sohn HS, Ryu H, Suh HS.

J Dent Res. 2015 Sep;94(9 Suppl):212S-9S. doi: 10.1177/0022034515587862. Epub 2015 May 22. Erratum in: J Dent Res. 2016 Jan;95(1):121.

PMID:
26001708
13.

Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.

Migliario M, Mergoni G, Vescovi P, Martino I, Alessio M, Benzi L, Renò F, Fusco V.

Dent J (Basel). 2017 Mar 16;5(1). pii: E13. doi: 10.3390/dj5010013.

14.

Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.

Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, Smeets R, Otto S.

J Craniomaxillofac Surg. 2018 Sep;46(9):1515-1525. doi: 10.1016/j.jcms.2018.05.046. Epub 2018 May 31.

PMID:
29983309
15.

The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.

Carlson ER, Basile JD.

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):85-95. doi: 10.1016/j.joms.2009.01.006.

PMID:
19371819
16.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY.

Bone. 2008 May;42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18. Review.

PMID:
18314405
17.

What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.

Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S.

J Craniomaxillofac Surg. 2017 Sep;45(9):1493-1502. doi: 10.1016/j.jcms.2017.05.028. Epub 2017 Jun 3. Review.

PMID:
28687467
18.

Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.

Ghidini G, Manfredi M, Giovannacci I, Mergoni G, Sarraj A, Mureddu M, Giunta G, Bonanini M, Meleti M, Vescovi P.

Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.

PMID:
28497661
19.

Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw.

Kang MH, Lee DK, Kim CW, Song IS, Jun SH.

J Korean Assoc Oral Maxillofac Surg. 2018 Oct;44(5):225-231. doi: 10.5125/jkaoms.2018.44.5.225. Epub 2018 Oct 26. Erratum in: J Korean Assoc Oral Maxillofac Surg. 2018 Dec;44(6):302.

20.

Supplemental Content

Support Center